Tian Xu
Gründer bei Shanghai Drug Farm Biological Technology Co., Ltd.
Profil
Tian Xu has founded Shanghai Drug Farm Biological Technology Co., Ltd.
in 2015 and currently holds the position of Chairman.
Aktive Positionen von Tian Xu
| Unternehmen | Position | Beginn |
|---|---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
 Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development. | Gründer | 21.10.2015 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development. | Technology Services |
